• Home
  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Cardiology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma News
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Subscribe
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
Skip to content
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma News

BioPharma News

Biopharmaceutical industry analysis. Credible, reliable, equitable.

Subscribe
  • Home
  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Cardiology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma News
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Subscribe

nirmatrelvir

Posted inCOVID-19, Infections, New Drugs, Regulatory

Xocova: Powerful New Japanese Pill for Coronavirus Treatment

by Nik Resovski and Timur Burkhanayev November 27, 2022December 5, 2022

Ensitrelvir by Shionogi & Co. is a highly effective antiviral drug that works just as well as Pfizer’s Paxlovid.

coronavirus Omicron
Posted inCOVID-19, Infections, Research

Omicron Treatment: Most Effective Drugs

by Tanya von Reuss and Timur Burkhanayev August 31, 2022September 8, 2022

Efficacy of antivirals and monoclonal antibodies for outpatient treatment of COVID-19 infection with the Omicron variant of SARS-CoV-2 coronavirus.

Paxlovid (nirmatrelvir + ritonavir)
Posted inCOVID-19, Infections, Regulatory

Paxlovid for COVID-19 Treatment. All Details

by Tanya von Reuss and Timur Burkhanayev August 24, 2022March 10, 2024

Paxlovid: treatment efficacy, “Paxlovid mouth”, COVID-19 rebound, management of Omicron variant, treatment resistance, generics, mechanism of action, price.

Paxlovid (nirmatrelvir + ritonavir).
Posted inCOVID-19, Infections, Research

Paxlovid Works Against Omicron

by Mark Gubar January 18, 2022September 8, 2022

The newest COVID-19 treatment is highly effective against the Omicron variant of SARS-CoV-2 coronavirus.

Paxlovid (nirmatrelvir + ritonavir).
Posted inCOVID-19, Infections, New Drugs, Regulatory

Paxlovid Approved in the U.S.

by Tanya von Reuss December 22, 2021September 8, 2022

Pfizer’s oral antiviral drug has entered the world’s main pharmaceutical market.

BioPharma News Logo
Biopharmaceutical industry analysis.
© 2025 BioPharma News Powered by Newspack Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma News

Awareness and enlightenment are strengths.

BioPharma News is an amazing and trustworthy non-profit data analysis service that provides honest and objective reporting on the Pharma & Biotech industry. We would like to invite you to sign up for our weekly Newsletter to stay informed and uptodate.

Please check your inbox or spam folder for an email from [email protected] to confirm your subscription.

×